Covalent drug discovery has reshaped pharma, expanding targetable residues and warhead diversity. While GSH half-life remains key for intrinsic reactivity, consensus on optimal reactivity and potency metrics is lacking. This evolving field brings new warheads, mechanisms, and kinetics. This poster highlights novel kinetic parameters for GSH reactivity and X-Chem’s approach to de-risk covalent leads by measuring phospholipid/albumin binding and reduction potentials.